Neuroimaging Biomarkers In Alzheimer S Disease

In view of the growing prevalence of AD worldwide, there is an urgent need for the development of better diagnostic tools and more effective therapeutic interventions. Indeed, much work in this field has been done during last decades. As such, a major goal of current clinical research in AD is to improve early detection of disease and presymptomatic detection of neuronal dysfunction, concurrently with the development of better tools to assess disease progression in this group of disorders. All these putative correlates are commonly referred to as AD-related biomarkers. The ideal biomarker should be easy to quantify and measure, reproducible, not subject to wide variation in the general population and unaffected by co- morbid factors. For evaluation of therapies, a biomarker needs to change linearly with disease progression and closely correlate with established clinico-pathological parameters of the disease. There is growing evidence that the use of biomarkers will increase our ability to better indentify the underlying biology of AD, especially in its early stages. These biomarkers will improve the detection of the patients suitable for research studies and drug trials, and they will contribute to a better management of the disease in the clinical practice. Indeed, much work in this field has been done during last decades. The vast number of important applications, combined with the untamed diversity of already identified biomarkers, show that there is a pressing need to structure the research made on AD biomarkers into a solid, comprehensive and easy to use tool to de deployed in clinical settings. To date there are few publications compiling results on this topic. That is why when I was asked to address this task I accepted inmediately. I am happy to present you a bundle of the best articles published about biomarkers for Alzheimer’s disease in recent times.

Biomarkers in Alzheimer’s Disease provides a comprehensive overview of all modalities of Alzheimer’s disease biomarkers, including neuroimaging, cerebrospinal fluid, genomic, and peripheral systems. Each chapter integrates molecular/cellular abnormality due to Alzheimer’s disease and technological advancement of biomarkers techniques. The book is ideal for clinical neuroscience and molecular/cellular neuroscience researchers, psychiatrists, and allied healthcare practitioners involved in the diagnosis and management of patients with cognitive impairment and Alzheimer’s disease, and for differential diagnosis of Alzheimer’s disease with other non-Alzheimer’s dementia. Presents a comprehensive overview detailing all modalities of Alzheimer’s disease biomarkers Written for neuroscience researchers and clinicians studying or treating patients with Alzheimer’s Disease Integrates, in each chapter, the molecular/cellular abnormality due to Alzheimer’s disease and the technological advancement of biomarkers techniques

Subjective cognitive decline (SCD) with self-reported concerns and mild cognitive impairment (MCI) are well-established to be at increased risk of developing Alzheimer’s disease (AD) dementia and a clinical continuum of dementia progression as a spectrum of AD. AD may develop from SCD to MCI (early MCI and late MCI) and eventually to AD. Nevertheless, until recently little was known about their pathophysiology associated with cognitive-behavioral syndrome. Although for researchers, scientists and clinicians, the pathophysiology of AD spectrum is an intriguing issue, delineating it in a clear way is far from easy. Taken together, in-depth understanding of neuroimaging-based pathology behind cognitive impairments across AD spectrum may help to develop new strategy for the early diagnosis and treatment of AD. Neuroimaging has been thought to potentially reveal the pathological mechanisms of AD progression. Individuals across AD spectrum are often associated with anatomical and functional brain alterations and cognitive impairment, most of the pathophysiology will focus primarily on the brain. To investigate brain structures and functions associated with cognition, neuroimaging will be the most appropriate tool.

This fully updated volume provides an up-to-date and comprehensive overview of the current state of technologies helping to accelerate Alzheimer's disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer's disease field are performed. Written for the highly successful Methods in Molecular Biology series, chapters feature the kind of detailed implementation advice that leads to greater success in the lab or clinic. Authoritative and practical, Biomarkers for Alzheimer's Disease Drug Development, Second Edition seeks to inspire and inform future efforts to develop effective treatments for this devastating disease.

A lot of research on biomarkers for Alzheimer is being done in the last few decades. The aim of these studies is to find some method to ease the diagnosis of Alzheimers as early as possible. Such methods are a range of blood or CSF tests on one hand and several types of neuroimaging scans on the other. Many of the images coming both from laboratory and neuroimaging are very visual and illustrative. These images, accompanied by a short description, can perfectly explain the main results and usefulness of every biomarker. The objective of this book would be to summarize the most important studies made in this field. Few publications have systematically compiled results on this topic and only one as an atlas. Readers would be interested in this publication because it allows reviewing the current status of research by handily visualizing the results.

Dementia is a massive and increasing global problem, with the current prevalence anticipated to double every 20 years as people live longer. Neuroimaging in dementia is recommended by most clinical guidelines and its role has traditionally been to exclude a mass lesion, rather than to support a specific diagnosis. All radiologists will be aware of a steady rise in the number of requests for brain imaging in old people, but what can imaging reliably tell us and what kind of imaging should we use? In affluent societies we now have a range of structural and molecular brain imaging techniques at our disposal, with specific ligands and sophisticated image analysis techniques now available for clinical use. However, we have difficulty justifying which patients to scan, using which modality and when. We know that Alzheimer’s disease is the most common neuropathology contributing to a diagnosis of Alzheimer’s disease but we also know from large post-mortem studies that most brain pathology in those who have died with a diagnosis of dementia is mixed. Thus understanding different diseases that can cause dementia, how these co-exist or interact and appreciating that not all dementia is Alzheimer’s disease is important. Equally important is awareness of individual differences in response to a neuropathological burden and what factors provide resilience against dementia that might be maximized to reduce or postpone its impact. This issue draws together contributions from experts in their fields to provide clarity to the topic in a comprehensive collection of articles.

Nearly 5.3 million Americans are living with Alzheimer's disease, and 26.6 million people are affected worldwide. The Alzheimer's Disease Neuroimaging Initiative (ADNI), a public-private partnership, provides a publicly available, international database of clinical and imaging data to foster research and collaboration on Alzheimer's research worldwide. The Institute of Medicine held a workshop on July 12, 2010, to explore opportunities to use information from and partnerships formed because of ADNI to continue to improve the understanding and treatment of Alzheimer's disease.